Loading
A phase 1 trial of RP-3467 run by Repare Therapeutics, terminated.
Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06560632 by Repare Therapeutics, with 26 participants enrolled, started 2024-09-17. Conditions recorded: Advanced Solid Tumor. Interventions recorded: RP-3467 at assigned dose and schedule and Olaparib 200-300 mg BID, daily.
Shares Repare Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Repare Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Repare Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Repare Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Repare Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Repare Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Repare Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/